Is Biotech Venture Capital Drying Up?
Welcome to the 101 new subscribers who joined our LinkedIn newsletter last week ?? If not done yet, subscribe to join the 3,587 fans of the Pick of the Week!
After booming initial public offerings (IPOs) and a wave of funding during the COVID-19 pandemic, is the gold rush now over for biotech companies??
The recent economic downturn has caused financing for biotechs to drop by 48.6% compared to 2021, and last year saw volatility and market uncertainty drive down IPO proceeds by 93%.?
This means that investing is now a risky business for venture capital firms, causing them to become far more selective around which companies they actually invest in.
But just how long will the “biotech winter” last and how is it affecting the industry as a whole?
To find out more, read the full article: "Gold rush over: what happens to biotech now that venture capital is out of reach?"
?? More noteworthy articles from this week:
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community!?Click here?to join our mailing list.
Entrepreneur | M&A
1 年Maybe the industry needs a more focused approach and entrepreneurs/investors with more realistic expectations?